What is TEVA's current stock price?

As of now, TEVA is trading at $25.17, with a daily change of -1.45%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

TEVA Stock Analysis & IQ Rating | Teva Pharma

TEVA SYMBOL Badge

Teva Pharma

$25.17

-$0.37 | -1.45%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$ 26.38

MKT CAP

$ 29.67B

52W Low

$ 12.47

VOL

$ 1.94M

P/E Ratio

41.16

AVG VOL

$ 11.89M

RSI

74.48

TREND

Uptrend

TEVA Stock IQ

Login to see Teva Pharma (TEVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

TEVA Target Price

Login to display

Strengths

TEVA Rewards

Earnings are forecast to grow

TEVA Rewards

Upgraded on attractively valued

TEVA Rewards

Investors confidence is positive

Chart

$19.31 (+30.35%)

$18.81 (+33.81%)

$17 (+48.06%)

$16.57 (+51.90%)

1year

6month

3month

1month

TEVA Risk Level

TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

TEVA Analysts Opinion

TEVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

TEVA Analysts Opinion

TEVA Analysts opinion is positive and also has improved from the past 3 months

TEVA Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

91%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

92%

100%

TEVA Street Sentiment

TEVA Street Sentiment is extremely bullish and have positive views on the near-term outlook

TEVA Performance Sentiment

Sentiments overview associated with TEVA events and the stock performance.

91%

9%

Positive

Negative

31 out of 34
events present

3 out of 34
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$25.83

Resistance
Price

$18.95

Current Price Range

$25.83

Show methods +

Linked to TEVA

IQ

Close Price

Change

SNY

4.25

52.22

-0.21%

PFE

3.89

25.20

-2.33%

NVS

3.71

131.98

+0.06%

MRK

4.01

93.07

+0.51%

AZN

4.26

88.77

+0.17%

TEVA Latest Analysis +

Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock. A substantial insider sell was reported on November 10 by TEVA) based on the recent SEC filing.United States Securities and Exchange Commission on Monday outlined that Weiss executed a sale of 12300 shares of In the Tuesday'.s morning session Teva Pharmaceutical based in Israel is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit p

Tue Nov 11, 2025

$25.13 | +3.67%

Activity

Heres How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today. Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently Teva Pharmaceutical Indus has a market capitalization of $27.77 billion.

Mon Nov 10, 2025

$24.26 | +1.21%

Activity

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript.

Mon Nov 10, 2025

$24.26 | +1.21%

Activity

JP Morgan Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight Recommendation. Fintel reports that on November 6 2025 JP Morgan maintained coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) with a Overweight recommendation. Analyst Price Forecast Suggests 99.77% Downside

Fri Nov 7, 2025

$23.97 | -1.94%

Momentum

Rating

Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new multi-year high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Potential

TEVA Q3 Earnings & Revenues Beat Austedo Sales View Raised Stock Up. Teva stock jumps after third-quarter earnings and revenues top estimates driven by robust Austedo sales as well as United States generics growth.

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new all-time high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Potential

Teva Rockets Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations. Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo in the United StatesThe post Teva Rockets Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations appeared first on Investor'.s Business Daily.

Wed Nov 5, 2025

$24.56 | +19.80%

Earnings

Momentum

Teva Pharmas Key Branded Drugs Fuel Strong Revenue Growth Lifts Full-Year Profit Outlook. TEVA) reported its third-quarter 2025 financial results on Wednesday with total revenue of $4.48 billion beating analysts'. expectations of $4.35 billion according to .Revenues increased 3% year-over-year in United States dollars or 1% in local currency.Key brands continue to drive growth with revenues up 33% in local currency to $830 million.Austedo (Huntington’.s disease drug) sales increased 38%

Wed Nov 5, 2025

$24.56 | +19.80%

Earnings

Potential

Heres What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings. Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025 it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Wed Nov 5, 2025

$24.56 | +19.80%

Potential

FAQ About TEVA Stock Insights

What is TEVA current stock price?

What are TEVA stock strengths?

What risks are associated with TEVA stock?

When is TEVA next earnings report?

What is TEVA market cap and volume?

What is TEVA's current Stock IQ?

Should I buy TEVA stock right now?

Is TEVA a Strong Buy right now?

What does a 'Strong Buy' rating mean for TEVA?

What does a 'Strong Sell' rating mean for TEVA?

What factors influence TEVA's Stock IQ?

Explore our TEVA Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored TEVA Stock Strategies
Effective Risk Management

FIND US ON

Receive our TEVA Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

TEVA TEVA Badge

Teva Pharma

Current Price

$25.17

-$0.37 | -1.45%

52W High

$ 26.38

MKT CAP

$ 29.67B

52W Low

$ 12.47

VOL

$ 1.94M

P/E Ratio

41.16

AVG VOL

$ 11.89M

RSI

74.48

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

TEVA Rewards

Earnings are forecast to grow

TEVA Rewards

Upgraded on attractively valued

TEVA Rewards

Investors confidence is positive

Linked to TEVA

Symbol

IQ

Close

Change

SNY

4.25

52.22

-0.21%

PFE

3.89

25.20

-2.33%

NVS

3.71

131.98

+0.06%

MRK

4.01

93.07

+0.51%

AZN

4.26

88.77

+0.17%

TEVA Stock IQ

Login to unlock Teva Pharma (TEVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$19.31 (+30.35%)

$18.81 (+33.81%)

$17 (+48.06%)

$16.57 (+51.90%)

1year

6month

3month

1month

TEVA Analysts Opinion

TEVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

TEVA Analysts Opinion

TEVA Analysts opinion is positive and also has improved from the past 3 months

TEVA Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

91%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

92%

100%

TEVA Street Sentiment

TEVA Street Sentiment is extremely bullish and have positive views on the near-term outlook

TEVA Risk Level

TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

TEVA Performance Sentiment

Sentiments overview associated with TEVA events and the stock performance.

91%

9%

Positive

Negative

31 out of 34
events present

3 out of 34
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$25.83

Resistance
Price

$18.95

Current Price Range

$25.83

Show methods +

TEVA Latest Analysis

Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock. A substantial insider sell was reported on November 10 by TEVA) based on the recent SEC filing.United States Securities and Exchange Commission on Monday outlined that Weiss executed a sale of 12300 shares of In the Tuesday'.s morning session Teva Pharmaceutical based in Israel is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit p

Tue Nov 11, 2025

$25.13 | +3.67%

Activity

Heres How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today. Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently Teva Pharmaceutical Indus has a market capitalization of $27.77 billion.

Mon Nov 10, 2025

$24.26 | +1.21%

Activity

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript.

Mon Nov 10, 2025

$24.26 | +1.21%

Activity

JP Morgan Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight Recommendation. Fintel reports that on November 6 2025 JP Morgan maintained coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) with a Overweight recommendation. Analyst Price Forecast Suggests 99.77% Downside

Fri Nov 7, 2025

$23.97 | -1.94%

Momentum

Rating

Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new multi-year high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Potential

TEVA Q3 Earnings & Revenues Beat Austedo Sales View Raised Stock Up. Teva stock jumps after third-quarter earnings and revenues top estimates driven by robust Austedo sales as well as United States generics growth.

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new all-time high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]

Thu Nov 6, 2025

$24.46 | -0.57%

Earnings

Momentum

Potential

Teva Rockets Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations. Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo in the United StatesThe post Teva Rockets Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations appeared first on Investor'.s Business Daily.

Wed Nov 5, 2025

$24.56 | +19.80%

Earnings

Momentum

Teva Pharmas Key Branded Drugs Fuel Strong Revenue Growth Lifts Full-Year Profit Outlook. TEVA) reported its third-quarter 2025 financial results on Wednesday with total revenue of $4.48 billion beating analysts'. expectations of $4.35 billion according to .Revenues increased 3% year-over-year in United States dollars or 1% in local currency.Key brands continue to drive growth with revenues up 33% in local currency to $830 million.Austedo (Huntington’.s disease drug) sales increased 38%

Wed Nov 5, 2025

$24.56 | +19.80%

Earnings

Potential

Heres What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings. Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025 it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Wed Nov 5, 2025

$24.56 | +19.80%

Potential

Discover TEVA Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of TEVA. We're here to help you make informed investment decisions today.

FIND US ON

Receive our TEVA Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

TEVA Stock trends

TEVA Stock performance

TEVA Stock analysis

TEVA investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing TEVA

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing TEVA

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

TEVA Stock Analysis & IQ Rating | Teva Pharma

TEVA Stock IQ

TEVA Target Price

TEVA Risk Level

TEVA Analysts Opinion

TEVA Street Sentiment

TEVA Performance Sentiment

Technical Price Levels

Explore our TEVA Stock insights

Receive our TEVA Daily Alerts

TEVA Stock IQ

TEVA Street Sentiment

TEVA Risk Level

Technical Price Levels

Discover TEVA Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of TEVA. We're here to help you make informed investment decisions today.

Receive our TEVA Daily Alerts

TEVA Runner Alarm